

Notice of References Cited	Application/Control No. 10/786,491		Applicant(s)/Patent Under Reexamination GUYER, DAVID R.	
	Examiner Kimberly Chong		Art Unit 1635	Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
*	A	US-5,342,348	08-1994	Kaplan, Aaron V.	604/891.1
*	B	US-2002/0040015	04-2002	Miller et al.	514/185
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Drolet et al. Pharmacokinetics and Safety of an Anti-Vascular Endothelial Growth Factor Aptamer (NX1838) Following Injection into Vitreous Humor of Rhesus Monkeys. Pharmaceutical Research, 2000, Vol. 17, No. 12: pages 1503-1510. ✓
	V	Ruckman et al. 2'-Fluoropyrimidine RNA-based Aptamers to the 165-Amino Acid Form of Vascular Endothelial Growth Factor (VEGF165). J of Biol. Chem. 1998. Vol. 273: 20556-20567. The American Society for Biochemistry and Molecular Biology, Inc.
	W	Vinores, S. Technology evaluation: pegaptanib, Eyetech/Pfizer. Current Opinion Molecular Therapy 2003, Vol. 5(6): pages 673-679.
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.